We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · January 24, 2021

Clinical Efficacy and Safety of Alirocumab After ACS According to Achieved Level of LDL-C

Circulation

 

Additional Info

Circulation
Clinical Efficacy and Safety of Alirocumab After Acute Coronary Syndrome According to Achieved Level of Low-Density Lipoprotein Cholesterol: A Propensity Score-Matched Analysis of the ODYSSEY OUTCOMES Trial
Circulation 2021 Jan 13;[EPub Ahead of Print], GG Schwartz, PG Steg, DL Bhatt, VA Bittner, R Diaz, SG Goodman, JW Jukema, YU Kim, QH Li, G Manvelian, R Pordy, T Sourdille, HD White, M Szarek,

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading